Literature DB >> 18181515

Evaluation of an alternative S100b assay for use in cardiac surgery: relationship with microemboli and neuropsychological outcome.

D C Whitaker1, A J E Green, J Stygall, M J G Harrison, S P Newman.   

Abstract

INTRODUCTION: The aim of the study was to investigate the relationship between S100b release, neuropsychological outcome and cerebral microemboli. Peri-operative assay of the astroglial cell protein S100b has been used as a marker of cerebral damage after cardiac surgery but potential assay cross-reactivity has limited its specificity. The present study uses an alternative enzyme-linked immunoabsorbant assay (ELISA) for serum S100b that has documented sensitivity and specificity data in patients undergoing coronary artery bypass grafting (CABG).
METHODS: Fifty-five consecutive patients undergoing routine CABG surgery received serial venous S100b sampling at five time points: i) Pre-operative, ii) At the end of cardiopulmonary bypass (CPB), iii) 6 hrs, iv) 24 hrs and v) 48 hrs post skin closure. A previously described sandwich ELISA with monoclonal anti- S100b was used. This assay has a lower limit of detection of 0.04 microg/L and < 0.006% reactivity with S100a at a concentration of 100 microg/L S100a. Cerebral microemboli during surgery were recorded by transcranial Doppler monitor over the right middle cerebral artery. Evidence of cerebral impairment was obtained by comparing patients' performance in a neuropsychological battery of 9 tests administered 6-8 weeks post-operatively with their pre-operative scores.
RESULTS: There was a significant increase in S100b only at the end of bypass (mean 0.30 microg/L, SD +/- 0.33 and range .00 to 1.57). S100b levels at the end of bypass did not correlate with neuropsychological outcome or microemboli counts.
CONCLUSIONS: The low levels of S100b detected using the present assay, despite its high sensitivity and despite the routine use of cardiotomy suction, suggest that the assay may have higher specificity for cerebral S100b than previously used assays. There was no evidence that this assay is related to neuropsychological change or cerebral microemboli in cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18181515     DOI: 10.1177/0267659107083243

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  5 in total

1.  Comparison of S100B and NSE between cardiac surgery and interventional therapy for children.

Authors:  Yu Liu; Ying Xu; Da-zhen Li; Yuan Shi; Mao Ye
Journal:  Pediatr Cardiol       Date:  2009-05-27       Impact factor: 1.655

Review 2.  Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood.

Authors:  Jaclyn A Freudenberg; Kathryn Bembas; Mark I Greene; Hongtao Zhang
Journal:  Methods       Date:  2008-06-23       Impact factor: 3.608

3.  Gaseous microemboli in a pediatric bypass circuit with an unprimed venous line: an in vitro study.

Authors:  Andrea Hudacko; Alicia Sievert; Joseph Sistino
Journal:  J Extra Corpor Technol       Date:  2009-09

4.  Blood levels of S-100 calcium-binding protein B, high-sensitivity C-reactive protein, and interleukin-6 for changes in depressive symptom severity after coronary artery bypass grafting: prospective cohort nested within a randomized, controlled trial.

Authors:  Daniel M Pearlman; Jeremiah R Brown; Todd A MacKenzie; Felix Hernandez; Souhel Najjar
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

5.  Aortic Stiffness Is Related to the Ischemic Brain Injury Biomarker N-Methyl-D-aspartate Receptor Antibody Levels in Aortic Valve Replacement.

Authors:  Emaddin Kidher; Vanash M Patel; Petros Nihoyannopoulos; Jon R Anderson; Andrew Chukwuemeka; Darrel P Francis; Hutan Ashrafian; Thanos Athanasiou
Journal:  Neurol Res Int       Date:  2014-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.